Global and China Triptolide Market Size Forecast and In-Depth Research Report on Prospects, 2025–2031

4.3.4 Average Selling Price of Triptolide by Key Chinese Manufacturers (2020–2025) 4.4 Global Key Manufacturers’ Headquarters and Production Site Distribution for Triptolide 4.5 Establishment Years and Commercialization Dates of Triptolide for Global Key Manufacturers 4.6 Product Types and Applications of Triptolide Offered by Global Key Manufacturers 4.7 Industry Concentration and Competitive Landscape Analysis for Triptolide 4.7.1 Industry Concentration Analysis: Top 5 Global Producers’ Market Share in 2024 4.7.2 First-Tier, Second-Tier, and Third-Tier Triptolide Producers (Brands) Globally and Their Respective Market Shares 4.8 New Investments and M&A Activities 5 Analysis of Global Key Producers 5.1 Tokyo Chemical Industry 5.1.1 Tokyo Chemical Industry: Company Overview, Triptolide Production Base, Sales Regions, Competitors, and Market Position 5.1.2 Tokyo Chemical Industry’s Triptolide Product Specifications, Parameters, and Market Applications 5.1.3 Tokyo Chemical Industry’s Triptolide Sales Volume, Revenue, Pricing, and Gross Margin (2020–2025) 5.1.4 Tokyo Chemical Industry: Corporate Profile and Core Business 5.1.5 Latest Corporate Developments of Tokyo Chemical Industry 5.2 SenesTech 5.2.1 SenesTech: Company Overview, Triptolide Production Base, Sales Regions, Competitors, and Market Position 5.2.2 SenesTech’s Triptolide Product Specifications, Parameters, and Market Applications 5.2.3 SenesTech’s Triptolide Sales Volume, Revenue, Pricing, and Gross Margin (2020–2025) 5.2.4 SenesTech: Corporate Profile and Core Business 5.2.5 Latest Corporate Developments of SenesTech 5.3 Nacalai Tesque 5.3.1 Nacalai Tesque: Company Overview, Triptolide Production Base, Sales Regions, Competitors, and Market Position 5.3.2 Nacalai Tesque’s Triptolide Product Specifications, Parameters, and Market Applications 5.3.3 Nacalai Tesque’s Triptolide Sales Volume, Revenue, Pricing, and Gross Margin (2020–2025) 5.3.4 Nacalai Tesque: Corporate Profile and Core Business 5.3.5 Latest Corporate Developments of Nacalai Tesque 5.4 Johns Hopkins Medicine 5.4.1 Johns Hopkins Medicine: Company Overview, Triptolide Production Base, Sales Regions, Competitors, and Market Position 5.4.2 Johns Hopkins Medicine’s Triptolide Product Specifications, Parameters, and Market Applications

U.S. Stock Tracking – May 15, 2020

May 21: Opened down -5.28%, rallied to -0.86%, tested the low once, closed above the opening price at -2.78%, turnover rate 1.64%, market capitalization below enterprise value, held by 14 institutions (23.58% of shares), no analyst recommendations; worth monitoring but requires caution due to extremely low trading volume. IBIO (iBio, Inc.) A biotechnology company headquartered in New York, providing product development and manufacturing services to customers, collaborators, and third parties in the U.S. and internationally. Its service portfolio spans preclinical development, regulatory approval, commercial product launch, and ongoing commercial-stage requirements. Its lead therapeutic candidate is IBIO-CFB03, intended for systemic sclerosis, idiopathic pulmonary fibrosis, and other fibrotic diseases; it also develops candidate vaccines for third parties and offers a suite of product and process development, analytical, and manufacturing services. The company holds a licensing agreement with the University of Natural Resources and Life Sciences, Vienna; has established a strategic partnership with Beijing CC-Pharming Ltd.; and maintains collaboration agreements with AzarGen Biotechnologies (Pty) Ltd., Texas A&M University System, and the Fraunhofer Institute for Molecular Biology and Applied Ecology. Total revenue quadrupled in 2019 but declined by one-third over the trailing twelve months; the company has yet to achieve net profitability; cash on hand dropped to one-quarter of the prior year’s level in 2019; deferred revenue increased tenfold. The stock hit a low of $0.05 on November 19, 2019, and peaked at $3.40 on February 28, 2020. May 21: Opened up +3.26%, traded with volatility—dipped, surged, dipped again—closed above the opening price at +5.07%, turnover rate 9.86%, market capitalization above enterprise value, held by 24 institutions (12.67% of shares), no analyst recommendations; buying at current highs carries risk. SNES (SenesTech, Inc.) Develops technologies for managing animal pest populations via fertility control; founded in 2004 and headquartered in Phoenix, Arizona. The company offers ContraPest—a liquid bait targeting reproduction to limit fertility in both male and female rats for population control—and is developing a range of fertility control and animal health products, including wildlife fertility control, non-surgical abortion and sterilization, boar taint mitigation, and treatments for animal cancers. Total revenue fluctuated sharply, declining by half in 2019 versus the prior year; the company remains unprofitable; cash on hand fell by 60%. The stock peaked at $13.00 on January 6, 2020, and hit a low of $1.32 on May 18, 2020. May 21: Opened up +1.59%, traded with high volatility—dipped, surged, dipped again, surged, dipped, surged, dipped—closed below the opening price at -1.27%, turnover rate 7.39%, market capitalization above enterprise value, held by 26 institutions (21.78% of shares), two analysts recommended buying; however, the highest price poses risk, and extremely low trading volume makes it unsuitable for trading.

SenesTech Inc (SNES) Stock Overview and Product Profile

Oct 16, 2026

SenesTech Inc (NASDAQ:SNES) specializes in rodent fertility control using its EPA-registered product ContraPest. The page displays stock market data and company mission information.

Proactive financial news

2026-03-06

SenesTech Inc Expected to Post a Loss of 30 Cents a Share - Earnings Preview

2026-03-10

SenesTech to Post 2025 Results March 12, 5 p.m. ET Webcast

2026-03-12

SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

2026-03-12

SenesTech Lifts Online Sales 88%, Seeks New CEO

2026-05-14

SenesTech Stock (US8123281036): Q1 Earnings Miss with 11% Surge